Viking’s Weight-Loss Drug Has a New Selling Point: Fewer Injections

Viking’s weight-loss drug helped patients maintain most of their earlier weight loss with injections every two weeks or once a month. The result points to a possible advantage, but longer-term evidence is still needed.

Viking Therapeutics has shown that its experimental weight-loss drug may help patients keep weight off with fewer injections. In a market crowded with drugs promising weight loss, that could give Viking a clearer way to stand out.

Participants first took weekly injections of VK2735 for 21 weeks. Those who then switched to an injection every two weeks retained an average of 90% of the weight they had lost over the next 12 weeks. The monthly group retained 85%, compared with 61% for participants switched to placebo.

Why fewer injections matter

Weight-loss treatment does not end when a patient reaches a target weight. Keeping it off can mean staying on medication for years. If less frequent injections prove effective over longer periods, they could make treatment easier to stick with and give Viking a useful point of difference.

That is the investor case behind the results. It is also why the 12-week limit matters. This early study shows what happened over three months of maintenance dosing; it cannot yet tell investors whether the same approach will work over years. Viking’s injectable drug is in Phase 3 obesity trials, but the less frequent maintenance schedule still needs further testing.

Viking has shown a promising route into a fiercely competitive market. The next question is whether fewer injections can hold up as a long-term advantage.

Viking’s weight-loss drug helped patients maintain most of their earlier weight loss with injections every two weeks or once a month. The result points to a possible advantage, but longer-term evidence is still needed.